靶向唾液酸-Siglec在肿瘤免疫治疗中的研究进展  

Research progress on tumor immunotherapy targeting sialic acid-Siglec complexes

作　　者：许青 段嘉蓉 郑天清 Qing Xu;Jiarong Duan;Tianqing Zheng(Tianjin University,Tianjin 300072,China;Zhejiang University of Technology,Hangzhou 310014,China;Hangzhou Institute of Medicine Chinese Academy of Sciences,Hangzhou 310000,China)

机构地区：[1]天津大学,天津市300072 [2]浙江工业大学 [3]中国科学院杭州医学研究所

出　　处：《中国肿瘤临床》2025年第2期81-85,共5页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金面上项目(编号:22277109)资助。

摘　　要：肿瘤免疫疗法改善了许多患者的预后,但大多数肿瘤仍然对目前批准使用的肿瘤免疫疗法具有一定的耐药性,需要研究更为有效的新型靶点以及创新联合治疗方案来克服这些阻力。越来越多的证据表明,Siglec受体作为新型免疫检查点的巨大潜力。Siglec是唾液酸结合免疫球蛋白样凝集素。多数Siglec作为跨膜受体发挥免疫抑制作用,其识别并结合糖蛋白和糖脂上特定的唾液酸聚糖。唾液酸聚糖-Siglec相互作用通过多种方式促进肿瘤免疫逃逸微环境的形成,与肿瘤患者的不良预后密切相关。本文总结了Siglec受体作为有效的新型免疫检查点的有力证据,并就唾液酸-Siglec相互作用对肿瘤免疫的影响及靶向唾液酸-Siglec免疫检查点的肿瘤治疗方案进行讨论。While tumor immunotherapy has improved the prognosis of many patients,immunotherapy drug resistance develops in most tumors.Studies of new targets and therapies are needed to overcome this challenge.Growing evidence indicates that Siglecs function in immune checkpoints.Siglecs belong to a family of salivary acid-binding immunoglobulin-like lectins.The majority of Siglecs are immunosuppressive transmembrane proteins that bind to sialic acid-containing glycans on glycoproteins and glycolipids.Sialoglycan-Siglec interactions contribute to tumor immune escape and are strongly correlated with poor prognosis in tumor patients.This review will discuss Siglec function in immune checkpoints,and how the interaction between sialic acid and Siglecs regulates the tumor microenvironment to exert therapeutic effects.

关 键 词：唾液酸 SIGLEC 唾液酸酶 靶向药物递送 肿瘤 

分 类 号：R730.51[医药卫生—肿瘤]